Notice of Intent to Award Sole Source: Antiviral Medicine – Zanamivir (Relenza®)

This is a notice of intent to award a Firm Fixed Price (FFP), sole source purchase order to GlaxoSmithKline (GSK), 410 Blackwell St, Durham, NC 27701-3986 pursuant to Federal Acquisition Regulation (FAR) subpart 13.5, Simplified Procedures for Certain Commercial Products and Commercial Services.

Department of Homeland Security (DHS), Office of Procurement Operations (OPO), Office of Health Security (OHS) has a requirement in support of the Department’s Pandemic Workforce Preparedness Plan (PWPP) entitled “Antiviral Medicine—Zanamivir (Relenza)”. Market research for this acquisition, demonstrated that GSK is the only commercially available, that has been authorized by the FDA, to manufacture Relenza. The basic requirement is to:

acquire the antiviral medicine, Zanamivir - Relenza®, for the DHS antiviral stockpile to prepare for a highly pathogenic outbreak that could lead to a pandemic. The Period of Performance for this requirement is one 12-month base period, four consecutive 12-month option periods. More details can be found in the Statement of Work (SOW) under “Attachments”. The estimated total dollar value of this contract is $1,900,000.00.

Possible interested parties responding to this notice must show clear and convincing evidence that it possesses a solution with the technical capability to satisfy the requirement listed in Section 6 of the SOW are encouraged to reply to this notice to the points-of-contact below no later than March 13, 2024, 2:00 p.m. EST. Please ensure your response includes your company's name, a detailed technical capability statement and any other information that demonstrates their ability to meet the needs of the Government, UEI number, and point-of-contact name and email.

Responses are limited to no more than five pages. A determination by the Government not to compete this proposed contract action based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement.